Population analysis and tissue-level immune profiling of cutaneous toxicity to immune checkpoint inhibitors

Active Grant Awarded Last action

Award ID
K08AR088287
Recipient
Awarding agency
Obligated
$165,024

Award facts

Completion date 4% complete
Place of performance
Forest Hills, TN 37215, USA

Award details come from USAspending.gov.

About this award

The National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health within the Department of Health and Human Services, awarded Vanderbilt University Medical Center a grant of $165,024 on September 9, 2026, under CFDA 93.846, Arthritis, Musculoskeletal and Skin Diseases Research. The award is a career development award that funds research defining how immune checkpoint inhibitors (ICIs) alter drug hypersensitivity, with the applicant's stated long-term goal of building an independent translational program in immune-mediated skin disease.

Aim 1 uses FDA Adverse Event Reporting System (FAERS) analysis, pharmacovigilance, and electronic health record data to quantify how ICIs modify the risk and phenotype of cutaneous immune-related adverse events. Aim 2 determines how ICIs reprogram tissue-resident immune responses in ICI-induced Stevens-Johnson syndrome and toxic epidermal necrolysis compared with classical drug-induced cases.

The period of performance runs from September 9, 2026 through an ultimate completion date of June 30, 2031. Place of performance is Forest Hills, Tennessee 37215.

Description

Abstract
Immune checkpoint inhibitors (ICIS) enhance antitumor immunity by disrupting tolerance mechanisms, but in doing so they can also unmask latent autoreactivity. As a result, these therapies organ toxicity, particularly skin toxicity, which affects 30-60% of treated patients. The clinical spectrum is broad, ranging from mild self-limited rashes to life-threatening eruptions that resemble classical drug reactions such as stevens-johnson syndrome and toxic epidermal necrolysis (SJS/ten). Outside the ICI setting, these syndromes are tightly linked to HLA alleles and culprit drugs such as antibiotics and antiepileptics. Emerging evidence suggests that ICIS can act as a "first HIT," lowering thresholds of immune tolerance in the skin and enabling conventional or even unconventional drugs to act as a "second HIT." despite their clinical importance, the risk factors and mechanisms of ICI-associated severe skin toxicity remain poorly understood. This career development award seeks to define how ICIS perturb drug hypersensitivity. The applicant's long- term goal is to establish an independent translational research program in immune-mediated skin disease that integrates clinical, genomic, and spatial approaches. The immediate objectives are to (1) identify how ICIS modify the risk and phenotype of skin toxicity using pharmacovigilance and electronic health record data, and (2) determine how ICIS reprogram tissue-resident immune responses in ICI-induced SJS/ten compared to classical drug-induced cases. Understanding how ICI reshapes drug hypersensitivity is essential for predicting and preventing catastrophic toxicity in the growing population of patients treated with these therapies. In aim 1, we will analyze the FDA adverse event reporting system (FAERS) to quantify how ICIS modify the risk of ciraes across phenotypes. We will estimate interaction effects between ICIS and common culprit drugs and validate findings in a dermatologist-adjudicated vanderbilt EHR cohort, using natural language processing to identify cases and incorporating additional clinical and genetic variables. These analyses will establish phenotype-specific risk signatures for cutaneous ICI toxicity. In aim 2, we will integrate single-cell multiomics with spatial transcriptomics to define immune composition, clonal expansions, and cytotoxic programs in tissue from patients with ICI-induced SJS/ten. Analyses will be benchmarked against our reference atlas of more than 100 classical drug-induced SJS/ten. These studies will test the hypothesis that ICIS reprogram tissue-resident T cell states, define specific cytotoxic programs, and/or create a hyperinflammatory cytokine milieu that lowers thresholds for drug-induced cytotoxicity. Through this award, the applicant will receive mentored training in pharmacoepidemiology, electronic health record-based phenotyping, single-cell multiomics, and spatial biology. Together, the results will provide mechanistic insight into how checkpoint blockade reshapes drug hypersensitivity and establish the foundation for targeted strategies to mitigate these reactions.

Transactions

Action Obligated Date
Amendment $0
Original award $165,024

Quick answers

Who received award K08AR088287?

K08AR088287 was awarded to Vanderbilt University Medical Center by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 9, 2026.

How much is award K08AR088287 worth?

$165,024 has been obligated on K08AR088287.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award